START FREE TRIAL
Home Healthcare Teva Pharmaceutical

Teva Pharmaceutical

$19.00

SKU: TEVA Category:

Description

Teva Is Not Just a Generics Giant Anymore — Its Innovative Drugs Are Growing 32%!

 

Teva Pharmaceutical Industries Limited reported its third-quarter 2026 financial results within the context of its ongoing transition from a generics-focused company to a biopharma-oriented firm. The company’s revenue decreased 2% year-over-year to approximately $4.4 billion, driven primarily by declines in its generics segment—most notably from lower contributions related to generic REVLIMID. However, this reduction was partially offset by strong growth within its innovative portfolio, which surged 32%, supported by key products such as AUSTEDO, AJOVY, and UZEDY. These innovative products continue to demonstrate market momentum, prompting Teva to raise full-year guidance across all three. AUSTEDO, in particular, exceeded its $2.5 billion sales target a year early, with sustained growth prospects. Gross margins improved significantly to 58.7%, up by more than 340 basis points from the prior year, reflecting the higher-margin mix of innovative products and ongoing operational efficiencies.